

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
09 January 2025 (09.01.2025)



(10) International Publication Number
WO 2025/008643 A2

(51) International Patent Classification:

A61P 35/00 (2006.01) C07K 16/28 (2006.01)
C07K 14/725 (2006.01) C07K 16/30 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/GB2024/051771

(22) International Filing Date:

05 July 2024 (05.07.2024)

Published:

- without international search report and to be republished upon receipt of that report (Rule 48.2(g))
- with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/512,019 05 July 2023 (05.07.2023) US

(71) Applicant: **ENARA BIO LIMITED** [GB/GB]; Magdalen Centre, The Oxford Science Park, 1 Robert Robinson Avenue, Oxford OX4 4GA (GB).

(72) Inventors: **VON ESSEN, Magdalena**; c/o Enara Bio Limited, Magdalen Centre, The Oxford Science Park, 1 Robert Robinson Avenue, Oxford OX4 4GA (GB). **HOWIE, Duncan**; c/o Enara Bio Limited, Magdalen Centre, The Oxford Science Park, 1 Robert Robinson Avenue, Oxford OX4 4GA (GB). **MASON, Peter**; c/o Enara Bio Inc., Corporation Trust Center, 1209 Orange Street, Wilmington, County of New Castle, Delaware, 19801 (US). **LAM, Emily**; c/o Enara Bio Limited, Magdalen Centre, The Oxford Science Park, 1 Robert Robinson Avenue, Oxford OX4 4GA (GB). **CORNFORTH, Terri**; c/o Enara Bio Limited, Magdalen Centre, The Oxford Science Park, 1 Robert Robinson Avenue, Oxford OX4 4GA (GB).

(74) Agent: **PALMER, Ellen** et al.; Marlow International, Parkway, Marlow Buckinghamshire SL7 1YL (GB).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: BISPECIFIC POLYPEPTIDE MOLECULE

(57) Abstract: The present invention relates to bispecific polypeptide molecules capable of simultaneously binding to a disease associated antigen and a cell surface antigen expressed on the surface of an immune effector cell such as a T-cell resulting in the activation of the immune effector cell.



WO 2025/008643 A2